Orchid receives USFDA approvals for Cefadroxil ANDAs

19004 Investors following Orchid Chemical. Share this News with them.

0

Like this story, share it with millions of investors on M3

Orchid receives USFDA approvals for Cefadroxil ANDAs

Orchid receives USFDA approvals for Cefadroxil ANDAs

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Orchid’s Formulation & API facilities approved by UK MHRA Orchid's cephalosporin dosage form gets approval Orchid receives USFDA approvals for Cefotaxime Injection Orchid Chemicals witnessing buying interest ALSO READ See latest News about Orchid Chemical See previous management interviews See what other Experts & Brokerages are saying about Orchid Chemical Orchid Chemical BSE | NSE 25/05/12 Are Mutual Funds betting on Orchid Chemical?

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) today announced that it has received the formal approval from the USFDA for its Cefadroxil 500 mg Capsules and 1 g Tablets  ANDAs (Abbreviated New Drug Applications).

Orchid would be launching this oral cephalosporin product in the US through its distribution partner, Par Pharma.

With these approvals, Orchid's ANDAs approved till date rises to 17. The total number of ANDAs filed till date stands at 31.

Sourced from: Orchid Chemicals & Pharmaceuticals Ltd